MK-4305 Suvorexant

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：MK-4305 Suvorexant	Purity：98% min
CAS NO：1030377-33-3	Solubility：Soluble in DMSO
Molecular Formula：C₂₃H₂₃ClN₆O₂	Package：Package according to customer requirements
Molecular Weight：450.921	Storage：Store at -20℃

Quality control

COA

Remarks

Suvorexant, also known as MK-4305, is a dual orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. It is not currently approved for commercial use, but it has completed three Phase III trials. Results look promising. The recent FDA review showed that the drug is associated with increased somnolence the next day and users of higher doses had an increased rate of suicidal ideation. Suvorexant works by turning off wakefulness rather than by inducing sleep.

Properties:
Density: 1.419 g/cm3
Boiling Point: 669.803ºC at 760 mmHg
Flash Point: 358.884ºC

References

1: McGaughey G, Bayly CI, Cox CD, Schreier JD, Breslin MJ, Bogusky M, Pitzenberger S, Ball R, Coleman PJ. Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs. J Comput Aided Mol Des. 2014 Jan;28(1):5-12. doi: 10.1007/s10822-014-9710-x. Epub 2014 Feb 1. PubMed PMID: 24488306; PubMed Central PMCID: PMC3927067.

2: Hoyer D, DÃ¼rst T, Fendt M, Jacobson LH, Betschart C, Hintermann S, Behnke D, Cotesta S, Laue G, Ofner S, Legangneux E, Gee CE. Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front Neurosci. 2013 Dec 10;7:235. doi: 10.3389/fnins.2013.00235. eCollection 2013. PubMed PMID: 24368893; PubMed Central PMCID: PMC3857892.